The online news service NJ Spotlight hosted a half-day event on May 11, 2018, at the Hilton Garden Inn in Hamilton, New Jersey, titled “Marijuana Legalization in NJ: Understanding the Opportunity and Challenges.” The event was sponsored by WeedMaps, Archer Attorneys at Law, and the New Jersey Cannabis Industry Association (NJCIA).
The day began with opening remarks from NJ Spotlight CEO and founding editor John Mooney. Mooney stressed the importance of hearing from other voices in the cannabis industry outside of New Jersey on the processes they went through, which was a good transition to the keynote address from Colorado’s director of Marijuana Coordination Andrew Freedman (also of Freedman & Koski).
Freedman’s keynote address was titled “Lessons from States with Legal Marijuana: What NJ Needs to Know for Implementation.” He discussed some of the points of contention when a state goes through the legalization process, including
Freedman presented a slideshow with statistics to answer some of the questions listed above and explained some of their significance. For example, he showed data from several National Survey on Drug Use and Health (NSDUH) studies related to youth use of cannabis that did not show a clear trend statistically between pre- and post-legalization in Colorado.
Freedman also addressed four other areas that he considered important issues in Colorado: naïve users, two black markets, social equity, and the 80/20 problem. From the naïve user standpoint, Freedman stressed that education is key for ensuring public safety. He also cited two examples that Colorado implemented to address youth use: the first was a “Don’t be a rat” ad campaign that tried to deter youth use with the concept of being a lab rat if you use marijuana at a young age. The campaign was not considered successful. The second campaign was tested with a focus-group and has had much better results: “Protect What’s Next” is an ad campaign targeted at youth where they focus on their future goals and ask themselves “Will marijuana help me achieve those goals?”
Freedman took several audience questions on topics ranging from public use laws, savings versus cost for law enforcement, arrest rates, banking issues, and more. For more information on Freedman’s talk and to view his slides, visit the NJ Spotlight website (1).
There was also a panel discussion moderated by NJ Spotlight Editor-in-Chief Lee Keough. The panelists included
The panel covered a broad range of topics and how they apply to New Jersey’s cannabis legalization process. Some of the key points raised were decriminalization versus legalization and the different impact those laws would have in the state; social equity; liability issues; taxes; and law enforcement challenges. Near the end, the panel was opened up to audience questions and Freedman joined the group.
The event was very informative and raised many important questions for New Jersey lawmakers and citizens to consider. As the legalization process continues, New Jersey is in a position to be a leader for other states that want to legalize cannabis. Time will tell what the future holds for New Jersey’s drive to legalize cannabis and include social equity measures and regulations in their bills, but the initial conversations seem promising.
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
Assessing Cannabis as a Harm Reduction Strategy: Insights from a Large-Scale Study
November 19th 2024A New Zealand study aimed to assess cannabis use as a harm reduction tool. Findings highlight lifestyle factors, and suggest cannabis-focused harm reduction strategies in reducing other substance use such as alcohol.
Ep 23, Part III: Accreditation in the Cannabis Industry with Susan Audino
October 24th 2024In Part III of this episode, host Evan Friedmann is joined by Susan Audino, PhD, founder of S.A. Audino & Associates, LLC, and co-founder of Saturn Scientific, LLC, to examine the complexities of sampling in the cannabis industry, emphasizing the need for proper sampling plans, and methods.